|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
D
|
|
INDICATIONS:
|
|
Heart failure, congestive |
|
Hypertension, essential |
| |
|
|
SIDE EFFECTS:
|
|
abdominal pain |
|
anaphylactoid reactions |
|
angioedema |
|
arthralgia |
|
azotemia |
|
back pain |
|
chest pain (unspecified) |
|
cholestasis |
|
cough |
|
diarrhea |
|
dizziness |
|
elevated hepatic enzymes |
|
fatigue |
|
headache |
|
hepatic failure |
|
hepatic necrosis |
|
hepatitis |
|
hyperkalemia |
|
hypotension |
|
jaundice |
|
malaise |
|
nausea/vomiting |
|
orthostatic hypotension |
|
palpitations |
|
pruritus |
|
rash (unspecified) |
|
sinus tachycardia |
|
syncope |
|
teratogenesis |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
aortic stenosis |
|
autoimmune disease |
|
black patients |
|
bone marrow suppression |
|
breast-feeding |
|
cardiomyopathy |
|
cerebrovascular disease |
|
children |
|
collagen-vascular disease |
|
coronary artery disease |
|
dialysis |
|
elderly |
|
heart failure |
|
hepatic disease |
|
hyperkalemia |
|
hyponatremia |
|
hypotension |
|
hypovolemia |
|
immunosuppression |
|
low-density lipoprotein apheresis |
|
pregnancy |
|
renal artery stenosis |
|
renal disease |
|
renal failure |
|
|
ADULT DOSE:
|
|
Antihypertensive-Initial: Oral, 10 or 20 mg (base) once a day, the dosage being adjusted slowly (at 2-week intervals) and according to clinical response.
Maintenance: Oral, 20 to 80 mg (base) once a day or divided into two equal doses.
Note: An initial dose of 5 mg should be used in patients who are sodium- and water-depleted as a result of prior diuretic therapy, patients continuing to receive diuretic therapy, or in patients with a creatinine clearance of 30 to 60 mL per minute. An initial dose of 2.5 mg should be used in patients with a creatinine clearance of 10 to 30 mL per minute. Such patients should be kept under medical supervision for at least two hours after this initial dose (and for an additional hour after blood pressure has stabilized), to watch for excessive hypotension.
There are insufficient data for a dosage recommendation in patients with a creatinine clearance less than 10 mL per minute.
Vasodilator, congestive heart failure -Initial: Oral, 5 mg (base) twice a day, dosage adjusted weekly until effective clinical response is achieved.
Maintenance: Oral, 20 to 40 mg daily divided into two equal doses. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Safety and efficacy have not been established.
|
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|